Spark Investment Management’s Arbutus Biopharma ABUS Stock Holding History

Spark Investment Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-28,026	Closed	-$28K	–	88
2020 Q1	$28K	Buy	+28,026	New	+$75.8K	0.01%	334
2018 Q2	–	Sell	-12,000	Closed	-$60K	–	650
2018 Q1	$60K	Sell	12,000 -11,000	-48%	-$58.2K	﹤0.01%	576
2017 Q4	$116K	Buy	23,000 +11,400	+98%	+$66.8K	0.01%	611
2017 Q3	$71K	Buy	+11,600	New	+$49.6K	﹤0.01%	681
2014 Q3	–	Sell	-10,300	Closed	-$134K	–	662
2014 Q2	$134K	Hold	10,300	–	–	0.02%	537
2014 Q1	$221K	Hold	10,300	–	–	0.03%	503
2013 Q4	$81K	Hold	10,300	–	–	0.01%	577
2013 Q3	$71K	Sell	10,300 -2,400	-19%	-$13.2K	0.02%	530
2013 Q2	$59K	Buy	+12,700	New	+$60.1K	0.02%	412

Other funds holding ABUS

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Spark Investment Management's ABUS Position: Q2 2020 in Review

Spark Investment Management sold out of Arbutus Biopharma (ABUS) in Q2 2020, closing a stake of 28,026 shares — an estimated $28K sold.

Spark Investment Management first reported a position in ABUS in Q2 2013 and held it in 9 quarters. The position peaked at $221K in Q1 2014. 51 funds tracked by Wall St. Rank hold ABUS as of Q2 2020.

Spark Investment Management reported no remaining Arbutus Biopharma position as of Q2 2020 after selling out during the quarter.
Spark Investment Management sold 28,026 Arbutus Biopharma shares in Q2 2020, an estimated $28K.
Spark Investment Management first reported a position in Arbutus Biopharma in Q2 2013 and held it in 9 quarters.
Spark Investment Management's Arbutus Biopharma position peaked at $221K in Q1 2014.
51 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2020.

Based on Spark Investment Management's 13F filing for Q2 2020, filed 12 Aug 2020.